The research aims to advance a global understanding of susceptibility to severe disease and COVID-19 risk factors that could ultimately inform the creation of a COVID-19 susceptibility test.
This type of test could serve as a critical tool in managing the disease with greater precision, support preemptive detection and treatment of high-risk patients, aid ongoing reopening efforts, and inform therapeutic research and vaccine prioritization.
As part of the collaboration, NYBC will supply samples of cryopreserved peripheral blood mononuclear cells (PBMCs) acquired from COVID-19 positive patients who have donated to the organization and given consent for research.
GoodCell will analyse the samples using its proprietary assays to identify and validate indicators of COVID-19 morbidity and mortality.
Among the goals of the research is to understand correlations between COVID-19 severity and the presence of accumulated genetic variation that culminate in the expansion of detrimental mutations and damage to DNA within blood cells, a phenomenon known as clonal hematopoiesis.
Recent studies have established linkages between such genetic changes and an aberrant inflammatory response characterized by increased cytokines, which has been associated with severe COVID-19 clinical manifestations.
A recent statistical study has also revealed a linear correlation between age-related increase in the frequency of such accumulated genetic variations measured by our assay and the age-related increase in mortality of COVID-19 infected patients.
This finding indicates that the virus' high mortality rate among older individuals may be tied to these genetic mutations. It is hypothesized that these changes in DNA may contribute to extreme viral complications, such as acute respiratory distress syndrome, chronic lung injury, venous thrombosis, acute cardiac injury and chronic cardiac damage, resulting in cardiomyopathy.
Founded in 1964, New York Blood Center is a nonprofit organization that is one of the largest independent, community-based blood centers in the world.
GoodCell's platform combines personal biobanking, diagnostics and data to provide individuals and their families the ability to securely test, track and respond to health risks, while enabling the scientific community to advance diagnostics and drug development at scale to create next-generation safeguards for global health.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment